1. Introduction {#sec1-medicina-55-00414}
===============

Targeted therapies are developed to encompass the nonspecific toxicity associated to standard chemo-drugs and also to ameliorate the efficacy of treatment. Biological agents can be used alone, but very often a combination of targeted molecules and conventional anti-tumor drugs is used. This new strategy aims to a selectively killing of malignancy cells by targeting either the expression of specific molecules on cancer cell surface or the different activated molecular pathways that directed to tumor transformation \[[@B1-medicina-55-00414]\]. New therapeutic approaches include a combination of "old" anticancer drugs (i.e., chemotherapies) and innovative molecules (targeted agents). These procedures are planned to mark both primary and metastatic cancer cells. The current classification of cancer-hematology targeted drugs includes monoclonal antibodies (mAbs), small-molecule inhibitors (SMIs), interfering RNA (iRNA), microRNA, and oncolytic viruses (OV). Their mechanisms of action can be either tumor specific (by interfering with cancer cell membrane biomarkers, cell-signaling pathways, and DNA or epigenetic targets), or systemic, through triggering of the immune responses \[[@B2-medicina-55-00414],[@B3-medicina-55-00414],[@B4-medicina-55-00414]\].

Currently, scientific evidence is still low, to address therapeutic drug monitoring of mAbs and SMIs. In this scenario, their combination with adjuvant therapies may represent a promising cancer treatment approach \[[@B5-medicina-55-00414]\].

In 2001, the first selective ABL Tyrosin Kinase inhibitor (TKI, Imatinib) was approved by the US Food and Drug Administration (FDA) \[[@B6-medicina-55-00414]\]. This was quickly followed by the monoclonal antibody marking the CD20 antigen (anti-CD20mAb, Rituximab) \[[@B7-medicina-55-00414]\]. Both agents accounted the revolution in the management of patients with Chronic Myeloid Leukemia (CML) and non-Hodgkin's lymphoma (NHL), respectively. These drugs guarantee around 80% response rate; on the other hand, drug-resistance is still a limitation, and new generation TKIs are being developed to by-pass these matters.

Currently, various new molecules are developed against specific tumor cell targets. Among these, histone deacetylase inhibitors (HDACi) and DNA hypomethylating agents target genetic/epigenetic determinants central for tumor growth ablation. New peptide vaccines targeting novel tumor-associated antigens, alternative checkpoint inhibitors, and chimeric antigen against T receptor (CAR-T) of the lymphocytes are being developed for the patients who have failed classical immunotherapy (often anti-PD1/anti-PD-L1). Newer SMIs targeting a variety of oncogenic signaling are being advanced to overcome the emerging of resistance phenomena to the existing targeted drug procedures \[[@B8-medicina-55-00414]\]. Above [Table 1](#medicina-55-00414-t001){ref-type="table"} reviews currently open phase I/II/III clinical trials for onco-hematologic patients. The data in the table were collected from [clinicaltrils.gov](clinicaltrils.gov) (accessed on June 2019). It may provide a useful implement to oncologist who treat relapsed refractory hematology malignancy.

Thanks to unique mechanisms of action these drugs are part of the therapy for many anticancer protocols, including lung, breast, pancreatic, and colorectal tumors, as well as lymphomas, leukemia, and multiple myelomas (MM). Also, targeted therapies call for new approaches to evaluating treatment effectiveness, and to assess the patients' adherence to treatment \[[@B9-medicina-55-00414]\].

Although targeted drugs, primarily the mAbs administration, are better tolerated than conventional chemotherapy, they are recorded numerous adverse events, such as cardiac dysfunction, hypertension, acneiform rash, thrombosis, and proteinuria \[[@B10-medicina-55-00414]\]. Since, SMIs are metabolized preferentially by cytochrome P450 enzymes (CYP450), the pharmacokinetics variation and multiple drug interactions should be present \[[@B11-medicina-55-00414]\].

Finally, targeted therapy has raised new questions about the tailoring of cancer treatments to each patient's tumor profile, the estimation of drug response, and the public reimbursement of cancer care. In agreement with these and other criticisms, the intention of this review is to provide information about the overall biology and mechanism of action of target drugs for onco-hematology, including overall pharmacodynamics due toxicities, and eventually inefficacy of the therapy \[[@B12-medicina-55-00414]\]. The well-noted correlation between the individual genomics profile and overall pharmacokinetic are reported below. In addition, the economic impact of these drugs, which can exceed several-fold the cost of traditional approaches, may become a major issue in pharmacoeconomics; an early evaluation of outcomes and challenges are also reported in this issue.

2. The Biological Mechanism of Action of the Targeting Agents {#sec2-medicina-55-00414}
=============================================================

Traditional cytotoxic chemotherapy works mainly through the inhibition of cell division like as cytoskeleton inhibitors (i.e., tecans, vincristine)analogues of nucletides (i.e., 5-Fluorouracil, Gemcitabine). So, each normal cell in mitotic stage (e.g., hair, gastrointestinal epithelium, bone marrow) is affected by these drugs. In contrast, the mechanism of action of targeted agents block specifically the proliferation of neoplastic cells by interfering with specific pathways essential for tumor progression and growth ([Figure 1](#medicina-55-00414-f001){ref-type="fig"}). It is true that some of these molecular targets could be present also in normal tissues, but they are often abnormally expressed in cancer tissues because of genic alterations.

2.1. Monoclonal Antibodies {#sec2dot1-medicina-55-00414}
--------------------------

In the last decade, about 30 mAbs have been approved, almost the 50% of them for the hematology-cancer therapy. The backbone of a mAb includes the fragment antigen binding (Fab), which recognizes and engage antigens, thus targeting the specific counterpart on cancer cells which is the objective of such therapies \[[@B13-medicina-55-00414]\]. These antibodies agent, either as native molecules or conjugated to radioisotopes or toxins (viral molecules to interfere with cell vitality) exert their antineoplastic effects through different mechanisms: by engaging and arming host immune effectors (i.e., natural killer cells and the complement) against target cells; by binding to receptors or ligands, thereby interfering with essential cancer cell proliferation pathways; or by carrying a "lethal cargo", such as a radioisotope or toxin, to the target cell \[[@B14-medicina-55-00414],[@B15-medicina-55-00414]\]. Because they are protein in structure, mAbs denatured in the gastrointestinal tract, and for this reason, they are administered intravenously. In this way, they do not undergo hepatic metabolism thus escaping significant drug interactions via CYP450 pathway.

Latest 30 years, as biotechnology has evolved, the design of mAbs has changed. Immunized mice developed early molecules in this class against target antigens. The resulting mAbs comprised the entire murine immunoglobulins (Igs), which were, hypothetically, carrying a risk of antigenic reaction during parenteral administration. The primary adverse events for patients treated with these new drugs is forming anti-mouse immunoglobulin antibodies, which could counteract the effect of the therapeutic mAbs. To decrease these adverse reactions, was developed mAbs contain an enlarged proportion of human Ig components to reducing murine Ig components. So mAbs are defines as: chimeric antibodies (about 65% human), humanized antibodies (95% human), and human antibodies (100% human) \[[@B16-medicina-55-00414]\].

General precautions of mAbs include: (a) Co-administrations of vaccines may be avoided; (b) Herpes and Pneumocystis prophylaxis recommended in therapy influencing the immune surveillance system (i.e., Anti-CD52);

The mAbs were designed to affect several cellular pathways. An angiogenic inhibitor (i.e., Anti-VEGF) was currently investigated in NHL, MM, and myeloproliferative disorders \[[@B17-medicina-55-00414]\]. The major side effect regardless the risk of ischemic events.

Immunomodulators aimed to achieve blocking of inhibitory molecules on the cell surface of immune effectors (i.e., Anti PD-1, anti-CD30, anti CD52, anti-CTLA-4, and anti-CD80), were approved for the treatment of patients with Hodgkin Lymphoma (HL).

The first targeted therapies have developed through the study of the over/expression of markers on the surface of tumor cells (on lymphoma and leukemia cells) including the cluster of differentiation 20, 33, and 52 (CD20, CD33, and CD52). Targeting this molecule affects the overall humoral immune response, as CD20 is also expressed on normal lymphocyte B. This estimation has led to the administration the anti-CD20 mAb Rituximab for the treatment of autoimmune diseases such as rheumatoid arthritis \[[@B18-medicina-55-00414]\], and NHL \[[@B19-medicina-55-00414]\].

Moreover, mAbs might induce tumor cell death through direct and indirect mechanisms, all prominent in blocking several and different oncogenic pathways. mAbs are effective at multiple levels: surface molecules (neutralizing ligand-specific receptor interaction), receptors (competitive with a ligand for binding); receptor signaling (signal blocking), or intracellular molecules. Therapeutic mAbs, which are typically water soluble and large molecular weight (about 160 kDa), target extracellular molecule-inducing signals, such as receptor-binding sites and ligands.

Noteworthy, Brentuximab vedotin have a new peculiar mechanism of action. It is an anti-CD30 antibody-drug conjugate (mAbC) that delivers an anti-tubulin toxin that induces apoptotic cell death in CD30-expressing tumor cells. Brentuximab vedotin is a mAb with a regular action involving a multi-step progression: binding to CD30 on the cell surface recruits internalization of the mAbC-CD30 complex, which then transfers to the cytoskeleton structures, where the released toxin, the monoauristatin-E, rescinds the microtubule complex, inducing cell cycle arrest and apoptotic death of the CD30-expressing cell in replication stage. However, classical Hodgkin's lymphoma (HL) and T-anaplastic large cell lymphoma (ALCL) express CD30 as an antigen on the surface of their malignant cells \[[@B20-medicina-55-00414]\].

2.2. Small Molecule Inhibitors {#sec2dot2-medicina-55-00414}
------------------------------

SMIs are chemical agents with low molecular weight (inferior to 1 kDa) capable of entering into the targeted cells, thus blocking signaling pathway and interfering with downstream intracellular protein systems (i.e., TK signaling). These molecules consist of TKI, BKI, Aurora Kinase Inhibitors (AKI), proteosome Inhibitors and HDAC inhibitors. Tyrosine Kinases phosphorylate specific amino acid residues of intracellular substrates affecting angiogenesis and cell growth in normal and malignant tissues.

The SMls differ from mAbs in many ways: (i) they are usually orally administered rather than parenterally infused; (ii) they are generated via a step-by-step chemical practice, a method that is often much less expensive than the bioengineering (i.e., recombinant DNA techniques) required for mAbs generation \[[@B18-medicina-55-00414]\]; (iii) they reach fewer definite targeting than mAbs, as marked in the multitargeting nature of the kinase inhibitors \[[@B21-medicina-55-00414]\].

In contrast to mAbs, most of the SMIs are metabolized by the CYP450 enzymes family, which may consequence in drug-drug interactions with molecules such as warfarin, azole antimicotics, viral anti-protease, and the St. John's wort, known as unyielding CYP450-inhibitors \[[@B22-medicina-55-00414]\].

The mAbs have administered once every one-to-four weeks due to pharmacokinetic of T~1/2~ ranging from few days to few weeks. While most SMIs have half-lives of few hours and necessitate daily dosing., with the exception of few molecules (i.e., bortezomib) which is given intravenously, SMIs are administered per os (orally).

### 2.2.1. Kinase-Based Signaling Inhibitors {#sec2dot2dot1-medicina-55-00414}

Agents developed for blocking the signaling pathway includes: Tyrosin Kinase Inhibitors (TKIs), Bruton Kinase Inhibitors (BTKIs), Aurora Kinase Inhibitors (AKI) and SYK, PI3K Inhibitors.

Imatinib is the first FDA-approved SMIs (since 2002) for the treatment of CML. It inhibits a constitutive TK activities resulting from the translocation of chromosomes 9 and 22 (the Philadelphia chromosome), involving BCR and Abl genes. Because this molecular anomaly occurs in essentially all patients with CML, imatinib therapy results in a complete hematologic response in 98% of them \[[@B23-medicina-55-00414]\]. Novel TKI molecules to overcome the imatinib resistance due to ABL T315I was developed, Bosutinib \[[@B24-medicina-55-00414]\], Dasatinib \[[@B25-medicina-55-00414]\], Nilotinib \[[@B26-medicina-55-00414]\], and Ponatinib \[[@B27-medicina-55-00414]\]. Furthermore, these small molecules are not able to prevent cerebral metastasis \[[@B28-medicina-55-00414]\].

Other altered TK pathway, involved in myeloid and lymphoproliferative disorders are the Janus Kinase receptors (JAK1, JAK2, and JAK3), phosphatidylinositol-3-kinase (PI3K), MET mitogen-activated protein kinases (MAPK), RET, and RAF.

JAK family (JAK1, JAK2, and JAK3) members mediate cytokine signaling via downstream activation of the STAT family of transcriptional regulators. Activated STATs endorse multiple cellular actions, like differentiation, proliferation, migration, and apoptosis. In particular, JAK2 is mediated hematopoiesis via GM-CSF, leptin, IL3, erythropoietin, and thrombopoietin \[[@B29-medicina-55-00414]\]. Activation of JAKs are induced conformational changes of ligand-binding to cytokine receptors, which engage phosphotyrosine-binding domains and/or SRC homology-2, which leads to activation of STAT, Ras--MAPK, and PI3K--AKT signaling pathways. Mutations in JAK2 exon 12 in pseudokinase domain (JH2) and JAK2 Val617Phe in exon 14 have been identified in approximately 4% and 90% of PV cases respectively. Several agents to interfere with JAK/STAT pathway were deigned: Itacitinib is a selective JAK1 inhibitor \[[@B30-medicina-55-00414]\]; Momelotinib and Ruxolitinib are both JAK1-2 inhibitor \[[@B31-medicina-55-00414],[@B32-medicina-55-00414]\].

MET, is a receptor tyrosine kinase that, after binding with hepatocyte growth factor (HGF), activates the PI3K and MAPK pathways. Over-expression of MET gene and exon-14-skipping mutations are characteristic abnormalities causing increased MET signaling progression. Cabozantinib is unique MET Inhibitor studied in phase 1b study in patients with relapsed MM \[[@B33-medicina-55-00414]\].

The PI3K pathway is an essential mediator of cell survival signals. Several molecules PI3K-p110 α,γ,δ sub unit inhibitor were under trial phase 1--2 for NHL, like as AMG319 \[[@B34-medicina-55-00414]\], Buparlisib \[[@B35-medicina-55-00414],[@B36-medicina-55-00414]\], Copanlisib \[[@B37-medicina-55-00414]\], CUDC-907 with additional inhibition of HDAC \[[@B38-medicina-55-00414]\], Dactolisib with additional inhibition on mTOR-p70S6K \[[@B39-medicina-55-00414]\], Duvelisib \[[@B40-medicina-55-00414]\], Getadolisib is a pan-PI3K, mTOR inhibitor. Its safety and maximum tolerated dose have been recently established in a phase 2 study of AML and CML \[[@B41-medicina-55-00414]\]. Idelalisib currently approved use for CLL \[[@B42-medicina-55-00414],[@B43-medicina-55-00414]\], INCB040093 \[[@B44-medicina-55-00414]\], Pictilisib \[[@B45-medicina-55-00414]\], and Taselisib the ultra-selective isoform-sparring PI3K-p110 α,γ,δ \[[@B46-medicina-55-00414]\], TGR-1202 \[[@B47-medicina-55-00414]\] also tested in combination with brentuximab in HL \[[@B48-medicina-55-00414]\] and Voxtalisib \[[@B49-medicina-55-00414]\].

The RET proto-oncogene encodes a receptor TK for members of the glial cell line-derived neurotrophic factor (GDNF) family. Vandetanib \[[@B50-medicina-55-00414]\], sorafenib \[[@B51-medicina-55-00414],[@B52-medicina-55-00414]\], sunitinib \[[@B53-medicina-55-00414]\], and cabozantinib are multi-targeted TKIs with RET-blocking activity. They are currently tested in phase 2 trials for MM and ALL \[[@B54-medicina-55-00414]\].

BRAF is a downstream signaling mediator of KRAS, which activates the MAP kinase pathway. BRAF mutations are found in about 99% of cases of hairy cell leukemia \[[@B55-medicina-55-00414]\] and in several cases of MM. To date, Dabrafenib and Vemurafenib are FDA-approved for BRAF V600E-positive malignant melanomas, but clinical trials of phase 1--2 were currently performed \[[@B55-medicina-55-00414]\].

### 2.2.2. Bruton's Tyrosin Kinase Inhibitor {#sec2dot2dot2-medicina-55-00414}

BTK is a cytoplasmic TK essential for B-lymphocyte development, differentiation, and signaling. As known, humans X-linked agammaglobulinemia (XLA) caused by mutations in the BTK gene (usually D43R and E41K). Activation of BTK triggers step by step signaling events that culminates in the cytoskeletal rearrangements by Ca^2+^ recruitments and transcriptional regulation involving nuclear factor-κB (NF-κB). In B lymphocytes, NF-κB bind the BTK 5′UTR gene promoter and active gene transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional BTK \[[@B56-medicina-55-00414],[@B57-medicina-55-00414]\].

Based on these issues several molecules were developed to target BTK: Ibrutinib \[[@B58-medicina-55-00414]\], and idelalisib \[[@B42-medicina-55-00414]\].

### 2.2.3. Histone Deacetylase (HDAC) Inhibitors {#sec2dot2dot3-medicina-55-00414}

Gene expression is regulated primarily by histone acetylation and deacetylation mechanism; this process is essential for relaxing the condensed chromatin and exposes the promoter regions of genes to transcription factors. On the contrary, deacetylation catalyzed by histone deacetylases (HDACs) results in gene silencing \[[@B59-medicina-55-00414]\]. In leukemic cells, this equilibrium is disturbed, and therefore, HDAC inhibitors emerged as a striking therapeutic approach to revise therapy. Unlike, clinical activity of monotherapy with an HDAC inhibitor was low, with ORR of 17% for vorinostat and 13% for mocetinostat \[[@B60-medicina-55-00414]\], and no clinical response was achieved with entinostat monotherapy \[[@B61-medicina-55-00414]\]. In addition, Belinostat has been tested in elderly patients with relapsed AML \[[@B62-medicina-55-00414]\]. Since it is primarily metabolized by UGT1A1; the initial dose should be reduced if the beneficiary is acknowledged to be homozygous for the UGT1A1\*28 allele \[[@B63-medicina-55-00414]\]. Therefore, current studies focus on combination regimens of HDAC inhibitors with other epigenetic agents are still ongoing.

### 2.2.4. Proteosome Inhibitors {#sec2dot2dot4-medicina-55-00414}

The proteasome is the latest promising molecular target for cancer therapy, a large multimeric \[[@B64-medicina-55-00414]\]. The proteasome is a protein complex that degrades the damaged proteins, and neoplastic cells are highly needy on increased protein production and degradation. It has a crucial role in cell signaling, cell survival, and cell-cycle progression. For these issues, proteasome inhibition is a core of therapy in lymphoid malignancies. Furthermore, proteasome inhibitors, such as bortezomib \[[@B65-medicina-55-00414]\] and carfilzomib \[[@B66-medicina-55-00414]\], are currently integrated into major regimens for multiple myeloma (MM) and mantle cell lymphoma (MCL) patients. Recently, proteasome inhibitors have also been used for the treatment of the relapsed/refractory setting for other NHLs, such as follicular cell lymphoma (FCL) \[[@B67-medicina-55-00414],[@B68-medicina-55-00414]\].

3. Pharmacogenetics, Overall Pharmacokinetics {#sec3-medicina-55-00414}
=============================================

Genetic tests for targeted cancer therapy detect either acquired mutations in the DNA of cancer cells and or polymorphisms in all germinal cells. Genotyping the cancer cells can help guide the type of targeted treatment, and it can predict who may respond to planned therapy and who is not likely to have benefited.

Researchers have extensively studied these variants in genes in order to better understand cancer and to develop drugs to interfere with a specific step in cancer growth while doing minimal damage to normal cells. The first example was Dasatinib and Nilotinib designed to by-pass the acquired mutation T315I in *Abl* gene in LMC patients. Unluckily, not every cancer has these acquired mutations, and various hematologic-cancers cells without this genetic signature cannot benefit to personalized treatments.

Pharmacogenomic tests are important, also, for the pharmacoeconomic issue: targeted drugs are expensive, and they generally work efficacy only in cancer patients who carried a genetic marker. Genetic testing prior to beginning therapy is necessary to match the treatment up with the patients and cancers likely to benefit from them. In contrast, chemotherapic drugs are cheaper, but it based on the paradigm of the "trial and error" leading the hospitalization during treatments. Recently, to reduce pharmaceutical expenditure, a combination of 2 SMIs blocking 2 mutated genes (*BRAF* and *MET*) are performed in the unique formulation (encorafenib + binimatenib) for melanoma therapy. So, the route is also drawn for the onco-hematology \[[@B137-medicina-55-00414]\].

The most common targeted cancer drugs for which tests are available include:

Drugs that block growth signaling binding to receptors on the cell surface

Small molecules inhibitors are able to cross the cell membrane and block downstream the growing signals in the specific active site.

These pharmacogenetic tests are used to help adjust drug dosage for certain cancers. They help to inform the oncologist as to whether certain targeted cancer drugs may or may not work.

4. Outcomes and Challenges {#sec4-medicina-55-00414}
==========================

Generally, chemotherapy is administered intravenously in an ensured infusion area. Therefore, patient adherence to treatment regimens is gladly reviewed. Delays and omissions in chemotherapy dosages, whether they are the result of patient preference or treatment-related either toxicities or resistance, are immediately recognized and documented. In contrast, most SMIs (almost all are oral formulation) administered at home on a long-term daily scheduling, could be difficult to recognize adverse events in real time. Thus, the task of assessing patient adherence more closely resembles that encountered with therapies for chronic diseases such as diabetes and hypercholesterolemia, and in so-called "frail patients". Finally, a few studies published to date shown high variability and unpredictability about patient adherence to oral cancer treatment regimens \[[@B138-medicina-55-00414]\].

Targeted therapy offers new means to determine the best possible treatment. Moreover, estimation of treatment success could not be based on the reduction in neoplastic volume and/or evaluation of toxicity through the degree of myelosuppression severity as well as traditional chemotherapy. Targeted therapies could convey a clinical benefit by stabilizing tumors, rather than reducing the progression of the neoplastic population cells. It also must necessitate to a paradigm shift in the evaluating the effectiveness of therapy. To set up the optimum of targeted drugs in terms of dosing and efficacy, must be evaluated progressively several endpoints, such as tumor metabolic activity on positron emission tomography (PET) scans, levels of circulating neoplastic cells, and following levels of target molecules in tumor tissue \[[@B139-medicina-55-00414]\]. These actions introduce complexity and cost to medical activity. Also, repeated biopsies of tumor tissue may be untimely for patients and improper to institutional evaluation boards.

Even though these procedures introduces new economic considerations: (i) oral SMIs eliminate treatment costs associated with the hospitalized intravenous infusions; (ii) the biotechnical production of mAbs can improves costs exponentially; (iii) need to genotype or phenotype tumor tissue; and (iv) new competencies for oncologist about pharmacogenomic testing \[[@B140-medicina-55-00414]\].

In term of the expenses, the targeted therapy is widely most expensive than traditional approaches. For example, in colon cancer, multidrug treatment regimens containing bevacizumab or cetuximab increase the cost to about 500-fold (\$30,790 for 8 weeks of treatment), compared with fluorouracil/leucovorin-based regimen (\$63 for the same period) \[[@B141-medicina-55-00414]\].

Based on this consideration, clinicians and laboratorists have a duty to cooperate in evaluating the advantages and limitations, particularly regarding costs and applicability, of the pharmacogenomic tests most appropriate for routine incorporation in clinical practice \[[@B142-medicina-55-00414]\].

5. Conclusions and Future Outlook {#sec5-medicina-55-00414}
=================================

For decades, the hallmark of anticancer treatments has based on the cytotoxic chemotherapy. These molecules rapidly target mitotic cells, including, unluckily, not only cancer cells but also, normal tissues in physiological growing phase. As a result, many patients develop the general adverse drug reaction (ADR) toxicities such as gastrointestinal symptoms, myelosuppression, and alopecia.

The medical approach based on chemotherapy alone, or in combination with surgical, and/or radiation, has reached doubtful therapeutic advances in spite of many significant enhancements in such treatments. While chemotherapy rests the primarily support of the current treatment in onco-hematology, it is limited by a narrow therapeutic index, noteworthy toxicity leading to treatment discontinuations and frequently acquired resistance.

The targeted molecules are drugs manufactured to interfere with specific proteins necessary for tumor growth and progression.

The new oncologic challenges of the 3rd millennium are based on the developments of the targeted therapy, including OV, interfering RNA molecules, and microRNA \[[@B143-medicina-55-00414]\].

The OV is capable of selectively replicating in tumor cells, leading to their lysis. There is growing proof, in preclinical studies, on the combining synergistic effects of OV to several chemotherapies \[[@B144-medicina-55-00414]\].

However, it is imperative to define the molecular mechanisms involved in the beneficial aspect of an individual therapy approach, despite the medicine adopted. This field is now translated in the clinical application for Chimeric Antigen Receptor (CAR) T-Cell Therapy. Moreover, microRNAs, a family of small noncoding RNAs implicated in the anti-cancer activity of many therapeutic agents, are shown to serve as attractive targets for the oncogene c-Myc-based combination therapy \[[@B145-medicina-55-00414]\].

The mechanism of oxidative stress repeatedly described as a co-factor in cancer development could be a mechanism involved by cancer therapies. Many patients to decrease the side effect often need antioxidant supplementation to adjuvant therapy, which (i.e., Glutathione) \[[@B146-medicina-55-00414]\], natural remedies \[[@B147-medicina-55-00414]\], and other complementary and alternative medicines \[[@B148-medicina-55-00414]\].

In this scenario, the genes encoding the familiar hallmarks of cancer must detect growth factor (GF) and GF receptors, apoptosis, multi-drug resistance, neovascularization, and invasiveness must be analyzed deeply. Also, the genetic predisposition related to factors promoting genome instability, inflammation, deregulation of metabolism and the immune system evasion/damaging must identify \[[@B149-medicina-55-00414]\].

The ribosome-inactivating proteins (RIPs) are promising agents extracted from the plant with a complete damaging of the ribosomal activities \[[@B150-medicina-55-00414]\].

Unlikely, no upgrading was seen for primary lymphoma central nervous system (PLCNS) in term of targeted therapy. The use of SMIs in PCNS and as preventing metastasis has failed \[[@B28-medicina-55-00414]\]. Encouraging evidence supporting the addition rituximab to classical alkylating agents is growing, and a recent randomized trial (MATRix regimen) demonstrated a significantly better OS \[[@B151-medicina-55-00414]\].

Based on this rationale, the oncologist should assess advantages and limits, regarding applicability and expenditure of the most fitting pharmacological approach to performing a customized therapy.

Finally, the Pharmacogenomic tests are mandatory for cancer targeted therapy; it can detect the variants that code mutant proteins markers, thus identifying tumors that may be susceptible to targeted therapy.
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![Schematic of pathway inhibition by targeted agents and their effects on cell proliferation, apoptosis, metastasis and angiogenesis. Receptors for growth factors (VEGFR, FGFR, PDGFR) activate intracellular receptor tyrosine kinases (RTKs) and the downstream RAS/RAF/mitogen-activated protein extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, and promote the growth, migration, and morphogenesis of vascular endothelial cells, thus increasing vascular permeability.](medicina-55-00414-g001){#medicina-55-00414-f001}
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###### 

The most common agents suitable for onco-hematology targeted therapy.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agent (Brand Name)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Target(s)                                                                                                                                            FDA-Approved Indication(s)                                                                                                                                                                                 Clinical Trials ^\$^                              Toxicities, Side Effects, and Precautions                                                                                                                                                                                                                                                                                                                  Pharmacogenomic Annotations
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------
  AFM13 \[[@B69-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 CD30/CD16A                                                                                                                                           Under revision                                                                                                                                                                                             HL---phase I/II. (P)                              ND                                                                                                                                                                                                                                                                                                                                                         ND

  Alvespimycin \[[@B70-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         HSP90                                                                                                                                                Under revision                                                                                                                                                                                             MM---phase I. (P)                                 ND                                                                                                                                                                                                                                                                                                                                                         ND
  (IPI-493; 17-AG)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  AMG319 \[[@B34-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                PI3K-p110δ                                                                                                                                           Under revision                                                                                                                                                                                             NHL---phase I. (P)\                               ND                                                                                                                                                                                                                                                                                                                                                         ND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I (P)                                                                                                                                                                                                                                                                                                                                                                                            

  Apitolisib \[[@B71-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PI3K -p110α/β/δ/γ and mTOR                                                                                                                           Under revision                                                                                                                                                                                             NHL---phase I (P)                                 ND                                                                                                                                                                                                                                                                                                                                                         ND
  (GDC-0980 (RG7422)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Avelumab \[[@B72-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             PD-L1                                                                                                                                                Metastatic Merkel Cell Carcinoma                                                                                                                                                                           AML---phase I/II. (P)\                            fatigue, fever, colitis                                                                                                                                                                                                                                                                                                                                    ND
  (MSB0010718C)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      HL---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase III.                                                                                                                                                                                                                                                                                                                                                                                             

  Belinostat \[[@B62-medicina-55-00414]\] (Beleodaq)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 HDAC Inhibitor                                                                                                                                       Relapsed or refractory peripheral T-cell lymphoma (PTCL)                                                                                                                                                   HL---phase I/II. (U)\                             Thrombocytopenia, leukopenia, and\                                                                                                                                                                                                                                                                                                                         Confirm the presence of t(9;22)BCR/ABL fusion gene.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase I/II. (U)\                            anemia. Infection, hepatotoxicity, tumor lysis syndrome, embryo-fetal toxicity                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase II (U)                                                                                                                                                                                                                                                                                                                                                                                            

  Bendamustine \[[@B73-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         alkylating drug                                                                                                                                      CLL                                                                                                                                                                                                        HL---phase I/II. (U)\                             Myelosuppression, infections, tumor lysis syndrome, skin reactions                                                                                                                                                                                                                                                                                         ND
  (Treanda)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NHL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM and PLCNS---phase I/II (U)                                                                                                                                                                                                                                                                                                                                                                                

  Bevacizumab \[[@B74-medicina-55-00414]\] (Avastin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 VEGF Inhibitor (VEGF ligand)                                                                                                                         Metastatic carcinoma of the colon or rectum                                                                                                                                                                NHL---phase I/II. (P)\                            Gastrointestinal perforation; wound healing complications; hemorrhage; arterial and venous thromboembolism; proteinuria; hypertension. Discontinue use several weeks before elective surgery; do not restart until surgical incision has healed                                                                                                            VEGFA rs3025000 C \> T\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                       rs3025033 A \> G.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM and PCN- phase II (P).                                                                                                                                                                                                                                                                                                                                                                                    

  Blinatumomab \[[@B75-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Bispecific CD19 directed CD3/T-cell                                                                                                                  Relapsed or refractory B-cell precursor ALL Ph-negative                                                                                                                                                    AML Ph+---phase II. (U)\                          Infections                                                                                                                                                                                                                                                                                                                                                 Confirm the presence of t(9;22)BCR/ABL fusion gene.
  (Blincyto)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NHL---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                         

  Bortezomib \[[@B65-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           26S proteasome                                                                                                                                       MM, patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy                                                                                  HL---phase II. (P)\                               Peripheral neuropathy; myelosuppression; rash; constipation; diarrhea; edema; fatigue, malaise and weakness, nausea, appetite decreased constipation, peripheral vomiting and anemia                                                                                                                                                                       Monosomy 5/7 FLT3-ITD\
  (Velcade)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NHL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       ALK-1\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                       Del(5q).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I (U).                                                                                                                                                                                                                                                                                                                                                                                          

  Bosutinib \[[@B24-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Kinase inhibitor                                                                                                                                     Chronic, accelerated, or blast phase\                                                                                                                                                                      ALL Ph-positive---phase I/II. (U)                 diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.                                                                                                                                                                                                                                                          Confirm the presence of t(9;22)BCR/ABL fusion gene.
  (Bosulif)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Ph + CML, resistant or intolerant to prior therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Brentuximab vedotin \[[@B20-medicina-55-00414]\] (Adcetris)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        CD30                                                                                                                                                 HL after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.\                              NHL---phase II. (U)\                              Neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper\                                                                                                                                                                                                                                                                                CD30
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ALCL after failure of at least one prior multi-agent chemotherapy regimen.                                                                                                                                 cMPD---phase 0/II. (P)\                           respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia,\                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase 0/I/II. (P)\                          cough, and vomiting.                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase 0/I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     PLCNS---phase I/II. (P)                                                                                                                                                                                                                                                                                                                                                                                      

  Buparlisib \[[@B35-medicina-55-00414],[@B36-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  PI3K-p110α/β/δ/γ                                                                                                                                     Under revision.                                                                                                                                                                                            NHL---phase I/II. (U)\                            ND                                                                                                                                                                                                                                                                                                                                                         ND
  (BKM120)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CLL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
  (NVP-BKM120)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ALL---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I. (U)                                                                                                                                                                                                                                                                                                                                                                                           

  Cabozantinib \[[@B33-medicina-55-00414]\] (XL184)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 RET, MET and VEGFR2 Kinase inhibitor                                                                                                                 Advanced renal cell carcinoma after prior anti-angiogenic therapy/metastatic medullary thyroid cancer.                                                                                                     MM---phase I/II.\                                 diarrhea, fatigue, nausea, decreased appetite, palmar-plantar erythrodysesthesia syndrome (PPES), hypertension, vomiting, weight decreased, and constipation.                                                                                                                                                                                              Acquired mutation on FLT3 ITD, c-Kit D816V.
  (Cabometyx)/(Cometriq)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             AML---phase I.\                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I/II.                                                                                                                                                                                                                                                                                                                                                                                            

  Carfilzomib \[[@B67-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Proteasome Inhibitor                                                                                                                                 Multiple myeloma after at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.   NHL---phase I/II. (U)\                            Fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia.                                                                                                                                                                                                                                                                                 ND
  (KYPROLIS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         HL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I. ND\                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I. ND\                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I. ND                                                                                                                                                                                                                                                                                                                                                                                            

  Ceritinib \[[@B76-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ALK                                                                                                                                                  ALK-positive, metastatic non-small cell lung cancer (NSCLC) after progression on or intolerant to crizotinib.                                                                                              NHl---phase I/II ALK+ (U)\                        diarrhea, nausea, elevated transaminases, vomiting, abdominal pain, fatigue, decreased appetite, and constipation.                                                                                                                                                                                                                                         ALK gene rearrangement (FISH)\
  (Zykadia)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          AML---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                          or RT-PCR fusion gene.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I. (P)                                                                                                                                                                                                                                                                                                                                                                                           

  Cetuximab \[[@B77-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            EGFR (HER1/ERBB1)                                                                                                                                    Metastatic colorectal carcinoma (EGFR positive) refractory to irinotecan- based chemotherapy (as a single agent or with irinotecan).                                                                       MM---phase II (P)                                 Infusion reaction, dermatologic toxicity, interstitial lung disease, fever, sepsis, kidney failure, pulmonary embolus, diarrhea, nausea, abdominal pain, vomiting.                                                                                                                                                                                         EGFR protein expression positive KRAS codon 12 and 13 mutations negative.
  (Erbitux)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Copanlisib \[[@B37-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PI3K-p110α/δ                                                                                                                                         Under revision.                                                                                                                                                                                            NHL---phase I/II. (U)                             Hyperglycemia, hypertension, fatigue, diarrhea, neutropenia, anemia, hypertension.                                                                                                                                                                                                                                                                         ND
  (BAY 80-6946)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  CUDC-907 \[[@B38-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              PI3K-p110α and HDAC1/2/3/10                                                                                                                          Under revision.                                                                                                                                                                                            NHL---phase I/II (U)\                             ND                                                                                                                                                                                                                                                                                                                                                         MYC alterations.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase (P)                                                                                                                                                                                                                                                                                                                                                                                               

  Dactolisib \[[@B39-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PI3K- p110α/γ/δ/β and mTOR-p70S6K                                                                                                                    Under revision.                                                                                                                                                                                            ALL---phase I. (P)\                               ND                                                                                                                                                                                                                                                                                                                                                         t(9;22)
  (BEZ235)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           AML---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase (P).                                                                                                                                                                                                                                                                                                                                                                                             

  Daratumumab \[[@B78-medicina-55-00414],[@B79-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 CD38                                                                                                                                                 MM after at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI agent.                                             NHL---phase I/II. (U)\                            Infusion reactions, fatigue, nausea, back pain, pyrexia, cough, and upper respiratory tract infection.                                                                                                                                                                                                                                                     ND
  (Darzalex)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         CLL-phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                        

  Dasatinib \[[@B25-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ABL\                                                                                                                                                 Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia-Ph positive with resistance or intolerance to prior therapy including imatinib.                                                                   NHL---phase I/II (P)\                             Rash; pleural effusion; fluid retention; mucositis; myelosuppression; QT interval prolongation.                                                                                                                                                                                                                                                            Confirm the presence of t(9;22)BCR/ABL fusion gene\
  (Sprycel)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          BCR-ABL, SRC family, c-KIT, PDGFR                                                                                                                                                                                                                                                                                                                               HL---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                        T315I mutation-positive.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM and PCN---phase I/II (W).\                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                          

  Denileukin \[[@B80-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           CD25/IL2RA\                                                                                                                                          Persistent or recurrent cutaneous T-cell lymphoma CD25+.                                                                                                                                                   MM---phase I (U)\                                 Fever, management\                                                                                                                                                                                                                                                                                                                                         CD25 protein expression (IHC).
  Diftitox(Ontak)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    (diphtheria toxin)                                                                                                                                                                                                                                                                                                                                              cMPD---phase II. (U)\                             of vascular leak\                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase II. (P)\                              syndrome or dehydration to secondary to gastrointestinal toxicity.                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                          

  Denosumab \[[@B81-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            RANKL                                                                                                                                                Postmenopausal women with osteoporosis at high risk for\                                                                                                                                                   MM---phase II/III (U)\                            back pain, pain in extremity, hypercholesterolemia,\                                                                                                                                                                                                                                                                                                       RANKL protein expression (IHC).
  (Prolia)(Xgeva)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Fracture.                                                                                                                                                                                                  NHL---phase II. (U)\                              musculoskeletal pain, and cystitis.                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     HL---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                           

  Durvalumab \[[@B82-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            PDL-1                                                                                                                                                Under revision.                                                                                                                                                                                            HL---phase I/II. (U)\                             Diarrhea, colitis, increased lipase, myasthenia gravis, pericardial effusion, neuromuscular disorder.                                                                                                                                                                                                                                                      ND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase II.                                                                                                                                                                                                                                                                                                                                                                                             

  Duvelisib \[[@B40-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            PI3K -p110δ/γ                                                                                                                                        Under revision.                                                                                                                                                                                            NHL---phase I/II/III. (U)\                        ND                                                                                                                                                                                                                                                                                                                                                         ND
  (IPI-145)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         CLL---phase I/II/III. (U)\                                                                                                                                                                                                                                                                                                                                                                                   
  (INK1197)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ALL---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                          

  Elotuzumab \[[@B83-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            SLAMF7                                                                                                                                               Multiple myeloma\                                                                                                                                                                                          LS---phase III. (U)                               Fatigue, diarrhea,\                                                                                                                                                                                                                                                                                                                                        ND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          in combination with lenalidomide and after one to three prior therapies.                                                                                                                                                                                     pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper\                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       respiratory tract infection, decreased appetite, pneumonia.                                                                                                                                                                                                                                                                                                

  Entinostat \[[@B61-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           HDAC Inhibitor                                                                                                                                       Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor (ER)-positive breast cancer.                                                                                   HL---phase II. (P)\                               ND                                                                                                                                                                                                                                                                                                                                                         ND
  (MS-275)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NHL---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALAL---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I.\                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM and PCN---phase I.                                                                                                                                                                                                                                                                                                                                                                                        

  Entospletinib \[[@B84-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        SYK                                                                                                                                                  Under revision.                                                                                                                                                                                            NHL---phase I/II. (P)\                            Atrial fibrillation, back pain, chest pain.                                                                                                                                                                                                                                                                                                                ND
  (GS-9973)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CLL---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I. (U)                                                                                                                                                                                                                                                                                                                                                                                           

  Erlotinib \[[@B85-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            HER1/EGFR                                                                                                                                            Advanced or\                                                                                                                                                                                               cMPD---phase I/II. (P)\                           Rash and diarrhea.                                                                                                                                                                                                                                                                                                                                         EGFR protein expression (IHC) Check CYP3A4\*1B\
  (OSI-774)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              metastatic non-small cell lung cancer.                                                                                                                                                                     AML---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                          CEBPA mut.
  (Tarceva)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Everolimus \[[@B86-medicina-55-00414]\] (AFINITOR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 mTOR                                                                                                                                                 Advanced renal cell carcinoma after failure of treatment\                                                                                                                                                  HL---phase I/II. (U)\                             stomatitis, infections, rash, fatigue, edema, abdominal pain, fever, asthenia, cough,\                                                                                                                                                                                                                                                                     Immunoglobulin heavy chain variable gene somatic hypermutations (Ig-V_H)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          with sunitinib or sorafenib.                                                                                                                                                                               NHL---phase I/II. (U)\                            headache and decreased appetite.                                                                                                                                                                                                                                                                                                                           Del(5q).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM and PLCNS---phase I/II.\                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                       

  Galiximab \[[@B87-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             CD80                                                                                                                                                 Under revision                                                                                                                                                                                             HL---phase II. (P)\                               Abnormal liver function tests infections, low phosphate levels.                                                                                                                                                                                                                                                                                            ND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase I/II/III. (U)                                                                                                                                                                                                                                                                                                                                                                                    

  Gedatolisib \[[@B41-medicina-55-00414],[@B42-medicina-55-00414],[@B43-medicina-55-00414],[@B44-medicina-55-00414],[@B45-medicina-55-00414],[@B46-medicina-55-00414],[@B47-medicina-55-00414],[@B48-medicina-55-00414],[@B49-medicina-55-00414],[@B50-medicina-55-00414],[@B51-medicina-55-00414],[@B52-medicina-55-00414],[@B53-medicina-55-00414],[@B54-medicina-55-00414],[@B55-medicina-55-00414],[@B56-medicina-55-00414],[@B57-medicina-55-00414],[@B58-medicina-55-00414],[@B59-medicina-55-00414],[@B60-medicina-55-00414],[@B61-medicina-55-00414],[@B62-medicina-55-00414],[@B63-medicina-55-00414],[@B64-medicina-55-00414],[@B65-medicina-55-00414],[@B66-medicina-55-00414],[@B67-medicina-55-00414],[@B68-medicina-55-00414],[@B69-medicina-55-00414],[@B70-medicina-55-00414],[@B71-medicina-55-00414],[@B72-medicina-55-00414],[@B73-medicina-55-00414],[@B74-medicina-55-00414],[@B75-medicina-55-00414],[@B76-medicina-55-00414],[@B77-medicina-55-00414],[@B78-medicina-55-00414],[@B79-medicina-55-00414],[@B80-medicina-55-00414],[@B81-medicina-55-00414],[@B82-medicina-55-00414],[@B83-medicina-55-00414],[@B84-medicina-55-00414],[@B85-medicina-55-00414],[@B86-medicina-55-00414],[@B87-medicina-55-00414],[@B88-medicina-55-00414]\]\   PI3K-p110α/γ and mTOR                                                                                                                                Under revision.                                                                                                                                                                                            AML---phase II. (P)\                              ND                                                                                                                                                                                                                                                                                                                                                         ND
  (PF-05212384)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                         
  (PKI-587)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Gemtuzumab \[[@B89-medicina-55-00414]\] (Ozogamicin) (Mylotarg™)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   CD33 (immunotoxin)                                                                                                                                   Acute Myeloid Leukemia CD33 positive in first relapse(patients who are 60 years of age or older).                                                                                                          cMPD---phase I/II. (W)\                           Chills, fever, nausea, vomiting, headache, hypotension, hypertension, hypoxia, dyspnea, hyperglycemia.                                                                                                                                                                                                                                                     CD33 (cytofluorimetry)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase II (W).                                                                                                                                                                                                                                                                                                                                                                                          Del(5q)

  Givinostat \[[@B90-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           HDAC Inhibitor                                                                                                                                       Duchenne's muscular dystrophy and Becker's muscular dystrophy.                                                                                                                                             cMPD---phase II. (U)\                             Gastrointestinal toxicities, cardiac toxicities, diarrhea, fatigue, nausea, thrombocytopenia, anorexia, myelosuppression.                                                                                                                                                                                                                                  ND
  (ITF-2357)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         HL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                           

  HeFi-1 \[[@B91-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                CD30                                                                                                                                                 Under revision                                                                                                                                                                                             HL---phase I. (P)                                 ND                                                                                                                                                                                                                                                                                                                                                         ND

  90Y-Ibritumomab\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   CD20 (immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody Ibritumomab and the Linker chelator tiuxetan)   Relapsed or\                                                                                                                                                                                               NHL---phase II/III. (U)\                          Neutropenia, thrombocytopenia, anemia, gastrointestinal symptoms (nausea, vomiting, abdominal pain, and diarrhea), increased cough, dyspnea, dizziness, arthralgia, anorexia, anxiety and ecchymosis.\                                                                                                                                                     Mutations membrane-spanning 4-domains, subfamily A, member 1\
  Tiuxetan \[[@B92-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab refractory follicular non-Hodgkin's lymphoma.                                            CLL---phase II. (U)                               Myeloid malignancies and dysplasias.                                                                                                                                                                                                                                                                                                                       (MS4A1).
  (Zevalin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Ibrutinib \[[@B58-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Bruton's Kinase inhibitor-BTK                                                                                                                        Mantle cell lymphoma after at least one prior therapy\                                                                                                                                                     NHL---phase I/II. (U)\                            Thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal\                                                                                                                                                                                                                                                                                 Chromosome 17p deletion positive (FISH)\
  (Imbruvica)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Chronic lymphocytic leukemia after at least one prior therapy.                                                                                                                                             PLCNS---phase I/II (U)\                           pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite, peripheral edema,\                                                                                                                                                                              and p53 mutation screening.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I. (U)\                              arthralgia, stomatitis.                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                          

  Idelalisib \[[@B42-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PI3K p110 δ                                                                                                                                          Relapsed CLL/SLL after at least two prior systemic therapies, Relapsed FL and B-cell NHL after at least two prior systemic therapies.                                                                      HL---phase II. (P)\                               diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, rash, neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations and AST elevations.                                                                                                                                                                                   Chromosome 17p deletion positive (FISH)\
  (Zydelig)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          cMPD---phase I (P)                                                                                                                                                                                                                                                                                                                                                                                           and p53 mutation screening.

  Imatinib \[[@B23-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Bcr-Abl tyrosine kinase, PDGF, SCF and c-Kit                                                                                                         CML\                                                                                                                                                                                                       cMPD---phase I/II. (U)\                           Neutropenia, thrombocytopenia, hepatotoxicity, edema, nausea, vomiting, muscle cramps, musculoskeletal pain,\                                                                                                                                                                                                                                              Confirm the presence of t(9;22)BCR/ABL fusion gene\
  (Gleevec)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ALL-Ph positive\                                                                                                                                                                                           ALL---phase II. (U)\                              diarrhea, rash, fatigue and abdominal pain.                                                                                                                                                                                                                                                                                                                c-Kit-D816V mutation\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CML- PDGFR positive\                                                                                                                                                                                       NHL---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                          FIP1L1-PDGFRα.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Aggressive systemic mastocytosis-D816V c-Kit negative\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Hypereosinophilic syndrome (HES) FIP1L1-PDGFRα fusion gene\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Recurrent and/or metastatic dermatofibrosarcoma protuberans\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)---Kit (CD117) positive.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  INCB040093 \[[@B44-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            PI3Kδ inhibitor                                                                                                                                      Under revision.                                                                                                                                                                                            HL---phase I/II. (P)\                             Headache, increased alkaline phosphatase, abdominal pain, pyrexia, increased ALT and AST, thrombocytopenia, neutropenia and anemia.                                                                                                                                                                                                                        ND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase I (P)\                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I.(P)                                                                                                                                                                                                                                                                                                                                                                                            

  Ipilimumab \[[@B93-medicina-55-00414],[@B94-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  CTLA-4                                                                                                                                               Unresectable or metastatic\                                                                                                                                                                                NHL---phase I/II. (U)\                            Fatigue, diarrhea, pruritus, rash,\                                                                                                                                                                                                                                                                                                                        CTLA4 rs4553808.
  (Yervoy)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                melanoma.                                                                                                                                                                                                  HL---phase I. (U)\                                and colitis.                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I. (U)                                                                                                                                                                                                                                                                                                                                                                                           

  Iratumumab \[[@B95-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           CD30                                                                                                                                                 Under revision.                                                                                                                                                                                            HL---phase I/II. (U)\                             ND                                                                                                                                                                                                                                                                                                                                                         ND
  (MDX-060)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NHL---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                          

  Itacitinib (INCB039110) \[[@B30-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               JAK1 inhibitor                                                                                                                                       Under revision.                                                                                                                                                                                            HL---phase I/II. (P)\                             Fatigue, constipation and nausea.                                                                                                                                                                                                                                                                                                                          ND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                         

  Ixazomib \[[@B96-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Proteasome inhibitor                                                                                                                                 Multiple\                                                                                                                                                                                                  NHL---phase I/II. (U)\                            diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea, peripheral edema, vomiting, and back pain.                                                                                                                                                                                                                                        MYC Gene Mutation.
  (Ninlaro)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               myeloma after at least one prior therapy in combination with\                                                                                                                                              CLL---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          lenalidomide and dexamethasone.                                                                                                                                                                            AML---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                          

  JNJ-40346527 \[[@B97-medicina-55-00414],[@B98-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 CSF-1R                                                                                                                                               Under revision.                                                                                                                                                                                            HL---phase I/II. (P)                              Edema, nausea, vomiting and headache.                                                                                                                                                                                                                                                                                                                      ND

  Lebrikizumab \[[@B99-medicina-55-00414],[@B100-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               IL-13                                                                                                                                                Under revision.                                                                                                                                                                                            HL---phase I/II. (P)                              Musculoskeletal, infections.                                                                                                                                                                                                                                                                                                                               ND
  (TNX-650)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Lenalidomide \[[@B101-medicina-55-00414],[@B102-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Immunomodulatory effects, Angiogenesis Inhibitors                                                                                                    Multiple myeloma,\                                                                                                                                                                                         HL---phase II (U)\                                Embryo-fetal toxicity, neutropenia,\                                                                                                                                                                                                                                                                                                                       Del(5q).
  (Revlimid^®^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           myelodysplastic syndromes.                                                                                                                                                                                 NHL---phase I/II/III (U).\                        thrombocytopenia, blood clots, liver failure, skin reactions, tumor lysis\                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I/II. (U)\                            syndrome, diarrhea, itching rash, tiredness. new cancers (malignancies).                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II/IV. (U)\                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Anemia---phase III. (U)\                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                         

  Lucatumumab \[[@B103-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         CD40                                                                                                                                                 Under revision.                                                                                                                                                                                            HL---phase I/II. (U)\                             Anemia, infections, diarrhea, vomiting, pyrexia, nausea, hypotension.                                                                                                                                                                                                                                                                                      ND
  (HCD122)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NHL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I. (U)                                                                                                                                                                                                                                                                                                                                                                                           

  MDX-1401\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CD30                                                                                                                                                 Under revision.                                                                                                                                                                                            HL---phase I. (P)                                 ND                                                                                                                                                                                                                                                                                                                                                         ND
  \[[@B104-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Mocetinostat \[[@B60-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         HDAC Inhibitor                                                                                                                                       Myelodysplastic syndrome\                                                                                                                                                                                  HL---phase I/II. (U)\                             Gastrointestinal toxicities, cardiac toxicities, diarrhea, fatigue, nausea, thrombocytopenia, anorexia                                                                                                                                                                                                                                                     ND
  (MGCD0103)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Diffuse large B-cell lymphoma.                                                                                                                                                                             NHL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I. (U)                                                                                                                                                                                                                                                                                                                                                                                           

  Momelotinib \[[@B31-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          JAK1/2                                                                                                                                               Under revision.                                                                                                                                                                                            cMPD---phase I/II/III. (U)                        thrombocytopenia, diarrhea, headache, dizziness and nausea.                                                                                                                                                                                                                                                                                                JAK 1/2 mut.
  (CYT387)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Nilotinib \[[@B26-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Kinase inhibitor-ABL                                                                                                                                 Chronic Myeloid Leukemia\                                                                                                                                                                                  AML c-Kit-positive---phase I/II. (U)\             nausea, rash, headache, fatigue, pruritus, vomiting, diarrhea, cough, constipation, arthralgia, nasopharyngitis, pyrexia, night sweats, thrombocytopenia, neutropenia and anemia.                                                                                                                                                                          Confirm the presence of t(9;22)BCR/ABL fusion gene\
  (Tasigna)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               phase accelerated in\                                                                                                                                                                                      CML T315I positive (U)                                                                                                                                                                                                                                                                                                                                                                                       c-Kit, mutation\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          adult patients resistant to or intolerant to prior therapy that included imatinib.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      UGT1A1\*28 allele homozygotes rs8175347.

  Nivolumab \[[@B105-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PD-1                                                                                                                                                 Melanoma and disease progression following\                                                                                                                                                                HL---phase I/II. (U)\                             Rash, fatigue, dyspnea, musculoskeletal pain,\                                                                                                                                                                                                                                                                                                             ND
  (OPDIVO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.\                                                                                                                                         NHL---phase I/II. (U)\                            decreased appetite, cough,\                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Metastatic squamous non-small cell\                                                                                                                                                                        AML---phase I/II. (U)\                            nausea, and constipation.                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          lung cancer.                                                                                                                                                                                               MM---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                       

  Obinutuzumab \[[@B106-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        CD20                                                                                                                                                 Chronic lymphocytic leukemia in combination with chlorambucil.                                                                                                                                             NHL---phase I/II. (U)                             Infusion reactions, neutropenia, thrombocytopenia, anemia, pyrexia, cough, and\                                                                                                                                                                                                                                                                            ND
  (GA101)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             musculoskeletal disorder.                                                                                                                                                                                                                                                                                                                                  
  (Gazyva)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Ofatumumab \[[@B107-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CD20                                                                                                                                                 Chronic lymphocytic\                                                                                                                                                                                       HL---phase II. (U)\                               Neutropenia, pneumonia,\                                                                                                                                                                                                                                                                                                                                   ND
  (ARZERRA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               leukemia refractory to fludarabine and alemtuzumab.                                                                                                                                                        NHL---phase I/II. (U)\                            pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis and upper respiratory tract infections.                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     PLCNS---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                        

  Ofatumumab\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        CD20                                                                                                                                                 Chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.                                                                                                                                    NHL---phase I/II. (U)\                            Neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.                                                                                                                                                                                                              MS4A1.
  \[[@B108-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     PCN---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                          
  (Arzerra)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  (HuMax-CD20)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Olaparib \[[@B109-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Poly ADP Ribose Polymerase (PARP)                                                                                                                    Ovarian cancer with BRCA mutation.                                                                                                                                                                         NHL---phase II. (P)\                              anemia, nausea, fatigue (including asthenia), vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, nasopharyngitis/pharyngitis, cough, arthralgia/musculoskeletal\                                                                                                                                                                      PARP 1 V762A.
  (Lynparza)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         MM---phase II. (P)                                pain, myalgia, back pain, dermatitis/rash and abdominal pain/discomfort.                                                                                                                                                                                                                                                                                   

  ONO \[[@B110-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 BTK                                                                                                                                                  Under revision.                                                                                                                                                                                            NHL---phase I. (P)\                               ND                                                                                                                                                                                                                                                                                                                                                         ND
  (GS-4059)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CLL---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                        

  Palbociclib \[[@B111-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         kinase inhibitor: CDK4, CDK6                                                                                                                         Breast cancer HER2 negative, postmenopausal women with ER positive in combination with letrozole.                                                                                                          MM---phase I. (P)\                                neutropenia,\                                                                                                                                                                                                                                                                                                                                              HER2 protein overexpression negative (IHC) ER+.
  (Ibrance)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NHL---phase II. (U)\                              leukopenia, fatigue, anemia, upper respiratory infection, nausea, stomatitis,\                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (P)\                            alopecia, diarrhea, thrombocytopenia, decreased appetite, vomiting, asthenia,\                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I/II (P)                              peripheral neuropathy,\                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       and epistaxis.                                                                                                                                                                                                                                                                                                                                             

  Panobinostat \[[@B112-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        HDAC Inhibitor                                                                                                                                       Multiple myeloma refractory to at least 2 prior regimens, including bortezomib and an immunomodulatory agent.                                                                                              cMPD---phase I/II. (U)\                           Gastrointestinal toxicities, cardiac toxicities, myelosuppression, hemorrhage, infections, hepatotoxicity, embryo-fetal toxicity.                                                                                                                                                                                                                          JAK2V617F.
  (Farydak)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          AML---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I/II/III. (U)\                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     HL---phase I/II/III (U).\                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase I/II/III. (U)\                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                          

  Pazopanib\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         kinase inhibitor\                                                                                                                                    Advance renal cell carcinoma.                                                                                                                                                                              MM---phase II. (U)                                Increases in serum transaminase levels and bilirubin, diarrhea, hypertension, hair color changes (depigmentation), nausea, anorexia, and vomiting.                                                                                                                                                                                                         UGT1A1\*28 allele homozygotes (TA)7/(TA)7 genotype.
  \[[@B113-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (VEGFR) PDGFR, KIT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  (Votrient)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Pembrolizumab \[[@B114-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       PD-1                                                                                                                                                 Unresectable or\                                                                                                                                                                                           HL---phase I/II/III (U)\                          fatigue, cough, nausea, pruritus, rash, decreased appetite,\                                                                                                                                                                                                                                                                                               ND
  (MK-3475) (Keytruda)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    metastatic melanoma and disease progression following ipilimumab\                                                                                                                                          NHL---phase I/II. (U) MM---phase I/II/III. (U)\   constipation, arthralgia and diarrhea.                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          and, if BRAF V600 mutation positive, a BRAF inhibitor.                                                                                                                                                     AML---phase II. (P)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase II. (P)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I. (P)                                                                                                                                                                                                                                                                                                                                                                                          

  Pexidartinib \[[@B115-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        CSF1R, KIT and oncogenic FLT3 kinases                                                                                                                Under revision.                                                                                                                                                                                            HL---phase II (P)\                                hair color changes, fatigue, nausea, swelling around the eyes, abnormal taste, diarrhea, vomiting, and decreased appetite, liver enzyme elevations, hyponatremia, anemia, and neutropenia.                                                                                                                                                                 ND
  (PLX3397)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          AML---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                        

  Pictilisib \[[@B45-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PI3K-p110α/δ                                                                                                                                         Under revision.                                                                                                                                                                                            NHL---phase I. (P)                                ND                                                                                                                                                                                                                                                                                                                                                         ND
  (GDC-0941)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Polatuzumab vedotin \[[@B116-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 CD79b                                                                                                                                                Under revision.                                                                                                                                                                                            NHL---phase I/II (U)                              Neutropenia, peripheral sensory neuropathy, diarrhea, lung disorder, anaemia febrile.                                                                                                                                                                                                                                                                      ND
  (DCDS4501A) (RG7596)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Pomalidomide \[[@B117-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Immunomodulatory effects, Angiogenesis Inhibitors                                                                                                    Multiple\                                                                                                                                                                                                  NHL---phase I/II. (U)\                            fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia.                                                                                                                                                                                                             ND
  (Pomalyst)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              myeloma after two prior therapies including\                                                                                                                                                               cMPD---phase I/II/III (U).\                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          lenalidomide and bortezomib with disease progression on or within 60 days of completion of the\                                                                                                            AML---phase I (U)                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          last therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Ponatinib \[[@B27-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Bcr-Abl tyrosine kinase\                                                                                                                             Accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant\                                                                                                                        AML---phase I/II (U)\                             hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, arthralgia, nausea, and pyrexia, thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia.                                                                                                                                                                        Confirm the presence of t(9;22)BCR/ABL fusion gene\
  (Iclusig)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ABL, FGFR1-3, FLT3, VEGFR2                                                                                                                           to prior tyrosine kinase inhibitor therapy,\                                                                                                                                                               cMPD---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                       FLT3-mutation.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          resistant or intolerant to prior tyrosine kinase inhibitor therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Pracinostat \[[@B118-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         HDAC Inhibitor                                                                                                                                       Under revision.                                                                                                                                                                                            AML---phase I/II. (U)\                            Gastrointestinal toxicities, cardiac toxicities, diarrhea, fatigue, nausea, thrombocytopenia, anorexia.                                                                                                                                                                                                                                                    ND
  (SB939)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            cMPD---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                       

  Resminostat \[[@B119-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         HDAC Inhibitor                                                                                                                                       Liver cancer.                                                                                                                                                                                              HL---phase II. (P)\                               Myelosuppression, gastrointestinal toxicities and fatigue.                                                                                                                                                                                                                                                                                                 ND
  (4SC-201)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NHL---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                          

  Retaspimycin \[[@B120-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        HSP90                                                                                                                                                Under revision.                                                                                                                                                                                            MM---phase I. (P)                                 Fatigue, nausea, diarrhea, liver function test abnormalities.                                                                                                                                                                                                                                                                                              ND
  (IPI-504)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Rituximab \[[@B7-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             CD20                                                                                                                                                 Relapsed or\                                                                                                                                                                                               NHL---phase I/II/III. (U)\                        Lymphocytopenia; HBV ractivation; severe mucocutaneous reactions (e.g., Stevens-Johnson syndrome).                                                                                                                                                                                                                                                         MS4A1.
  (Rituxan)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              refractory low-grade\                                                                                                                                                                                      HL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
  (Mabthera)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              or follicular CD20\                                                                                                                                                                                        MM---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          positive B-cell\                                                                                                                                                                                           ALL-B---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          non-Hodgkin's\                                                                                                                                                                                             CLL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          lymphoma.                                                                                                                                                                                                  cMPD---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                         

  Romidepsin Depsipeptide \[[@B121-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             HDAC                                                                                                                                                 Cutaneous T-cell lymphoma after at least one prior systemic therapy.                                                                                                                                       NHL---phase I/II (U)\                             nausea, fatigue, infections, vomiting, and anorexia\                                                                                                                                                                                                                                                                                                       Del(5q).
  (Istodax))                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         MM---phase II. (U)\                               anemia, thrombocytopenia, ECG T-wave changes, neutropenia, and lymphopenia.                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     HL---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I(U)                                                                                                                                                                                                                                                                                                                                                                                             

  Ruxolitinib \[[@B32-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          JAK1/2                                                                                                                                               Intermediate or high-risk myelofibrosis, including primary myelofibrosis,\                                                                                                                                 HL---phase I/II. (P)\                             Thrombocytopenia and anemia\                                                                                                                                                                                                                                                                                                                               JAK 1/2 mutations.
  (Jakafi)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                post-polycythemia vera myelofibrosis\                                                                                                                                                                      NHL---phase I/II. (P)\                            bruising, dizziness and headache.                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          and post-essential thrombocythemia\                                                                                                                                                                        CML---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          myelofibrosis.                                                                                                                                                                                             MS---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                          

  SB-743921 \[[@B122-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Kinesin spindle protein                                                                                                                              Under revision.                                                                                                                                                                                            HL---phase II. (P)\                               ND                                                                                                                                                                                                                                                                                                                                                         ND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                          

  SGN-30 \[[@B123-medicina-55-00414]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               CD30                                                                                                                                                 Under revision.                                                                                                                                                                                            HL---phase I/II. (U)\                             Candidiasis, interstitial lung disease.                                                                                                                                                                                                                                                                                                                    ND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                          

  Siltuximab \[[@B124-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          IL-6                                                                                                                                                 Multicentric Castleman's disease HIV-negative and HHV-8-negative.                                                                                                                                          NHL---phase I (P)\                                pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection.                                                                                                                                                                                                                                                                    IL6 -174C \> G rs1800795.
  (CNTO 328)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        MM---phase I. (P)                                                                                                                                                                                                                                                                                                                                                                                            
  (Sylvant)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Sodium phenylbutyrate \[[@B125-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Urea cycle disorders\                                                                                                                                Urea cycle disorders.\                                                                                                                                                                                     CLL---phase I. (U)\                               Change in the frequency of breathing, lack of or irregular menstruation, lower back, side, or stomach pain, mood or mental changes muscle pain or twitching, nausea or vomiting\                                                                                                                                                                           CEBPA mut\
  (BUPHENYL^®^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      HDAC Inhibitor                                                                                                                                       Acute promyelocytic leukemia (APL).\                                                                                                                                                                       NHL---phase I. (U)\                               nervousness or restlessness\                                                                                                                                                                                                                                                                                                                               Confirm the presence of t(15;17) PML/RAR fusion gene in APL.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Malignant glioma.                                                                                                                                                                                          cMPD---phase I. (P)\                              swelling of the feet or lower legs\                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (U)\                            unpleasant taste unusual tiredness or weakness, chills, fever, joint pain,\                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I. (U)                                sore throat, unusual bleeding or bruising.                                                                                                                                                                                                                                                                                                                 

  Sonidegib \[[@B126-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Hedgehog\                                                                                                                                            Locally advanced basal cell carcinoma recurred following surgery or radiation therapy, or patients who are not\                                                                                            MM---phase II. (U)\                               muscle spasms, alopecia, dysgeusia, fatigue, nausea, musculoskeletal pain, diarrhea,\                                                                                                                                                                                                                                                                      ND
  (LDE225)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          pathway inhibitor                                                                                                                                    candidates for surgery or radiation therapy.\                                                                                                                                                              ALL---phase II. (U)\                              decreased weight, decreased appetite, myalgia, abdominal\                                                                                                                                                                                                                                                                                                  
  (Odomzo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Medulloblastoma.                                                                                                                                                                                           AML---phase II (U)\                               pain, headache, pain, vomiting, and pruritus.                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II (U).                                                                                                                                                                                                                                                                                                                                                                                       

  Sorafenib \[[@B51-medicina-55-00414],[@B52-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Multikinase inhibitor\                                                                                                                               Advanced renal cell carcinoma.                                                                                                                                                                             NHL---phase I/II (P)\                             Hypertension; alopecia; bleeding; rash; hand-foot syndrome; hypophosphatemia; elevated amylase and lipase levels; myelosuppression; wound-healing complications.                                                                                                                                                                                           VEGFR, PDGFR, Kit, BRAF acquired mutation for prevention resistance\
  (BAY43-9006)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      (BRAF and mutant BRAF,\                                                                                                                                                                                                                                                                                                                                         HL---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                        CEBPA mutations, TET2 mutations, DNMT3 mutations, MLL-PTD mutations.
  (Nexavar)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-β)                                                                                                                                                                                                                                                                                                                      AML---phase I/II/IV (U)\                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase II. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM and PLCNS---phase I/II (P).                                                                                                                                                                                                                                                                                                                                                                               

  Sunitinib \[[@B53-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Multikinase inhibitor (PDGFRα, PDGFRβ VEGFR, KIT, FLT3, CSF-1R, RET)                                                                                 Gastro intestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. Advanced renal cell carcinoma.                                                                           cMPD---phase II (U)\                              Yellow of skin; hypothyroidism, adrenal function abnormalities; myelosuppression; mucositis; elevated lipase and creatinine levels; elevated liver chemistries; increased uric acid levels.                                                                                                                                                                Genotype for CYP3A4. Dose reductions for CYP3A4 Poor Metabolizer (PM).
  (Sutent)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NHL---phase I/II (P)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II/IV (P).\                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase I/II (P)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                          

  Tanespimycin \[[@B127-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        HSP90                                                                                                                                                Under revision.                                                                                                                                                                                            AML---phase I. (P)\                               Abdominal pain, hepatotoxicity.                                                                                                                                                                                                                                                                                                                            ND
  (KOS-953)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         CML---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                          
  (17-AAG)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           cMPD---phase I (P)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I. (P)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase II/III (P).\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                          

  Taselisib \[[@B46-medicina-55-00414]\] (GDC-0032)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  β isoform-sparing PI3K-p110α/δ/γ                                                                                                                     Under revision.                                                                                                                                                                                            NHL---phase I. (P)                                ND                                                                                                                                                                                                                                                                                                                                                         ND

  Tazemetostat \[[@B128-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Inhibitor of EZH2                                                                                                                                    Under revision.                                                                                                                                                                                            NHL---phase I/II (P)                              Asthenia, thrombocytopenia, nausea, constipation, anemia, dry skin, hypophosphatemia, anxiety, depression, hypertension, insomnia, peripheral edema, hepatocellular injury.                                                                                                                                                                                ND
  (EPZ-6438)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Temsirolimus \[[@B129-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        mTOR                                                                                                                                                 Advanced renal cell carcinoma.                                                                                                                                                                             HL---phase I/Ia---(P)\                            ash, asthenia, mucositis, nausea, edema, and anorexia,\                                                                                                                                                                                                                                                                                                    ND
  (Torisel)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NHL---phase I/II. (P)\                            anemia, hyperglycemia, hyperlipemia,\                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (P)\                           hypertriglyceridemia, elevated alkaline phosphatase, elevated serum creatinine, lymphopenia, hypophosphatemia, thrombocytopenia, elevated\                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CML---phase I/II. (P)\                            AST, and leukopenia.                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase II. (P)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM and PCN---phase I/II (P).                                                                                                                                                                                                                                                                                                                                                                                 

  TGR-1202 \[[@B47-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             PI3K p110 δ                                                                                                                                          Under revision.                                                                                                                                                                                            CLL---phase I/II. (P)\                            Colitis and hepatic toxicity, opportunistic infections.                                                                                                                                                                                                                                                                                                    ND
  (RP5264)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           HL---phase I/II. (P)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase I/II. (P)                                                                                                                                                                                                                                                                                                                                                                                        

  Thalidomide \[[@B130-medicina-55-00414]\] (Thalomid)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Immunomodulatory effects, Angiogenesis Inhibitors                                                                                                    Multiple myeloma in combination with bortezomib or dexamethasone.                                                                                                                                          NHL---phase I/II/I (W)\                           infections, back pain, pyrexia, acute renal failure, amenorrhea, aphthous stomatitis, bile duct obstruction, carpal tunnel, diplopia, dysesthesia, dyspnea, enuresis, erythema nodosum, foot drop, galactorrhea, gynecomastia, hangover effect, hypomagnesemia, hypothyroidism, metrorrhagia, migraine, myxedema, nodular sclerosing Raynaud's syndrome.   5p deletion.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     HL---phase I/II. (W)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I/II. (W)                                                                                                                                                                                                                                                                                                                                                                                        

  Tositumomab \[[@B131-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         CD20                                                                                                                                                 CD20 positive, follicular, non Hodgkin lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy.                                        MM and PCN---phase I/II (U).\                     Severe cytopenias, anaphylaxis, secondary malignancies, nausea, fatigue, infections, vomiting, anorexia, chills, Hypotension, Hypothyroidism, peripheral edema, myalgia, arthralgia.                                                                                                                                                                       ND
  (Iodine-131)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      LS---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
  (Bexxar)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NHL---phase I/II/III (U).\                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     HL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                        

  Trametinib \[[@B132-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Kinase inhibitor\                                                                                                                                    Unresectable or metastatic Melanoma with BRAF V600E or V600K mutations.                                                                                                                                    MM---phase I/II. (P)\                             Rash, diarrhea, and lymphedema.                                                                                                                                                                                                                                                                                                                            BRAF V600E or V600K mutations MEK protein overexpression positive (IHC).
  (Mekinist)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         (MEK)                                                                                                                                                                                                                                                                                                                                                           AML---phase I/II. (P)                                                                                                                                                                                                                                                                                                                                                                                        

  Tremelimumab \[[@B133-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        CTLA-4                                                                                                                                               Under revision.                                                                                                                                                                                            NHL---phase I. (U)\                               Diarrhea, fatigue, hot flashes and hives.                                                                                                                                                                                                                                                                                                                  ND
  (Ticilimumab)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase I (U).                                                                                                                                                                                                                                                                                                                                                                                            
  (CP-675,206)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Vandetanib \[[@B50-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Kinase inhibitor (EGFR-HER1/ERBB1, RET, VEGFR2)                                                                                                      Symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced.                                                                                                        MM---phase II. (U)                                Diarrhea, rash, acne, nausea, hypertension, headache, fatigue, decreased appetite and abdominal pain.                                                                                                                                                                                                                                                      Acquired mutation for prevention resistance.
  (ZD6474)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  (Caprelsa)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Vemurafenib \[[@B55-medicina-55-00414]\] (Zelboraf)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Kinase inhibitor (BRAF)                                                                                                                              Unresectable or metastatic Melanoma with BRAF V600E\                                                                                                                                                       MM---phase I/II. (P)\                             Arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus and skin papilloma.                                                                                                                                                                                                                                                       BRAF V600E/K mutation positive.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Mutation.                                                                                                                                                                                                  HCL---phase II. (U)                                                                                                                                                                                                                                                                                                                                                                                          

  Venetoclax \[[@B134-medicina-55-00414]\] (Venclexta)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               BCL-2                                                                                                                                                CLL after at least one prior therapy.                                                                                                                                                                      NHL---phase I. (U)\                               Neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia.                                                                                                                                                                                                                                                                17p deletion.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I. (U)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                        

  Vismodegib \[[@B135-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Hedgehog pathway inhibitor                                                                                                                           Metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma recurred following surgery or not candidates for surgery or radiation.                                                      NHL---phase II (U)\                               muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia.                                                                                                                                                                                                          ND
  (Erivedge)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         CLL---phase II. (P)\                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cMPD---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AML---phase II (U)                                                                                                                                                                                                                                                                                                                                                                                           

  Vorinostat \[[@B61-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           HDAC Inhibitor                                                                                                                                       Cutaneous T-cell lymphoma, progressive, persistent or recurrent disease on or following two systemic therapies.                                                                                            AML---phase I/II, (U)\                            Diarrhea, fatigue, nausea, thrombocytopenia, anorexia, dysgeusia, creatininemia.                                                                                                                                                                                                                                                                           ND
  (SAHA)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            cMPD---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                      
  (Zolinza)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CML---phase I/II/III (U)\                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NHL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     MM---phase I/II/III (U)\                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     HL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CLL---phase I/II. (U)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ALL---phase I/II. (U)                                                                                                                                                                                                                                                                                                                                                                                        

  Voxtalisib \[[@B49-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           mTOR/PI3K-p110γ                                                                                                                                      Under revision.                                                                                                                                                                                            NHL---phase I/II. (P)\                            ND                                                                                                                                                                                                                                                                                                                                                         ND
  (SAR245409) (XL765)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                CLL---phase I/II. (P)                                                                                                                                                                                                                                                                                                                                                                                        

  Ziv-aflibercept \[[@B136-medicina-55-00414]\]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     VEGF-A                                                                                                                                               Metastatic colorectal cancer resistant to or has progressed following an oxaliplatin-containing regimen, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI).                             MM---phase II. (P)\                               leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, thrombocytopenia, ALT increased, dysphonia, serum creatinine increased.                                                                                                                                                                                                         ND
  (Zaltrap)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          cMPD---phase II. (P)                                                                                                                                                                                                                                                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\$^ The molecules should be either in preclinical stage (P), in clinical use (U) and/or withdrawn/obsolete (W). Abbreviations. ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; CLL/SLL: Chronic lymphocytic leukemia/small lymphocytic leukemia; DLBCL: Diffuse large B cell lymphoma; HL: Hodgkin lymphoma; FL: Follicular lymphoma; HCL: Hairy cell leukemia; HG-BCL: High grade B-cell lymphoma; IGHV: Immunoglobulin G heavy variable chain; iNHL: indolent NHL; IV: intravenous; MCL: Mantle cell lymphoma; MM: Myeloma multiple; MDP: Myeloproliferative disorders; MZL: Marginal zone lymphoma; PLCNS: Primary lymphoma of central nervous system; ND: Not documented; pts: patient. Note: the present table could be not exhaustive of all current agents used for onco-hematology.
